| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(91)90543-X |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:014067369190543X?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:014067369190543X?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1714529 |
| P2093 | author name string | R. J. Lee | |
| W. M. Garraway | |||
| G. N. Collins | |||
| P2860 | cites work | Reproducibility of uroflowmetry variables in elderly males | Q38154742 |
| Are Doctors Able to Assess Prostatic Size? | Q39521988 | ||
| A Technical and Clinical Evaluation of The Disa Uroflowmeter | Q39831034 | ||
| Transabdominal ultrasound in the evaluation of prostate size | Q47267249 | ||
| Some clinical aspects of uroflowmetry in elderly males. A population survey | Q68972653 | ||
| Natural history of benign prostatic hypertrophy | Q68972823 | ||
| The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study | Q70043674 | ||
| The development of human benign prostatic hyperplasia with age | Q72743475 | ||
| A simple uroflowmeter tester | Q72776628 | ||
| P433 | issue | 8765 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostatic hypertrophy | Q506659 |
| P304 | page(s) | 469-471 | |
| P577 | publication date | 1991-08-01 | |
| 1991-08-24 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | High prevalence of benign prostatic hypertrophy in the community | |
| P478 | volume | 338 |
| Q80297770 | 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia |
| Q93811583 | 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia |
| Q51518468 | A High-Efficiency Microwave Thermoablation System for the Treatment of Benign Prostatic Hyperplasia: Results of a Randomized, Sham-Controlled, Prospective, Double-Blind, Multicenter Clinical Trial |
| Q50241539 | A Prospective Study to Evaluate Sexual Dysfunction and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Benign Prostatic Hyperplasia by Alpha Blockers. |
| Q72070464 | A Study of Benign Prostatic Hyperplasia—a Challenge to British Urology |
| Q50617870 | A cost density analysis of benign prostatic hyperplasia |
| Q34485381 | A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride |
| Q30629338 | A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate. |
| Q47975152 | A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia |
| Q58272320 | ABSTRACTS OF The 2nd Asian ISSAM Meeting on the Aging Male Taipei, Taiwan March 6–9, 2003 |
| Q39467122 | Accurate Determination of Prostate Size Via Digital Rectal Examination and Transrectal Ultrasound |
| Q36174660 | Acute urinary retention in men: the risks and outcomes with medical therapy |
| Q36900815 | Acute urinary retention: medical management and the identification of risk factors for prevention |
| Q43211514 | Alfuzosin hydrochloride transdermal films: evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters |
| Q41182587 | Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia |
| Q44285299 | Ambulatory care program for patients presenting with acute urinary retention secondary to benign prostatic hyperplasia |
| Q49569643 | An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied wi |
| Q42598720 | Anabolic-androgenic steroid effects on early morbid symptoms after open prostatectomy: a pilot study |
| Q71771009 | Analysis of the prevalence of voiding symptoms in Maori, Pacific Island, and Caucasian New Zealand men |
| Q64054687 | Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications |
| Q28571464 | Angiotension II receptor 1 blocker modifies the expression of apoptosis-related proteins and transforming growth factor-beta1 in prostate tissue of spontaneously hypertensive rats |
| Q37799171 | Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis |
| Q38711334 | Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study |
| Q48577104 | Association between lower urinary tract symptoms and erectile dysfunction |
| Q82714985 | BPH: unmet needs in managing LUTS--a European perspective |
| Q42443827 | Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. |
| Q63966029 | Benign prostatic hyperplasia |
| Q77065476 | Benign prostatic hyperplasia |
| Q93706088 | Benign prostatic hyperplasia |
| Q30463989 | Benign prostatic hyperplasia |
| Q35537838 | Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment |
| Q36392187 | Benign prostatic hyperplasia. Part 1--diagnosis |
| Q36859820 | Benign prostatic hyperplasia. Practical treatment guidelines |
| Q33358316 | Benign prostatic hyperplasia: a highly prevalent disease in the elderly |
| Q35070768 | Benign prostatic hyperplasia: a progressive disease of aging men. |
| Q40394761 | Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions |
| Q56898498 | Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia |
| Q34053394 | Blebbistain, a Myosin II Inhibitor, as a Novel Strategy to Regulate Detrusor Contractility in a Rat Model of Partial Bladder Outlet Obstruction |
| Q32063011 | Catheter-free endoscopic laser ablation of the prostate using a 1-size prostatic stent |
| Q46956272 | Central obesity as a risk factor for prostatic hyperplasia. |
| Q36853498 | Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forager-Horticulturalists |
| Q35720576 | Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia |
| Q74046419 | Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs |
| Q44028373 | Characterization of some novel alpha 1-adrenoceptor antagonists in human hyperplastic prostate |
| Q30435930 | Clinical ease of using doxazosin in BPH patients with and without hypertension |
| Q37456781 | Clinical significance of postvoid residual volume in older ambulatory women |
| Q37258873 | Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia |
| Q45980134 | Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. |
| Q34962509 | Community-based research on the benign prostatic hyperplasia prevalence rate in Korean rural area. |
| Q28542960 | Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis |
| Q44428229 | Comparative population-based survey as evaluation method of prostate disease changes |
| Q40954829 | Comparison of Nonspherical Polyvinyl Alcohol Particles and Microspheres for Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperplasia |
| Q42484157 | Comparison of marker protein expression in benign prostatic hyperplasia in vivo and in vitro |
| Q41465608 | Conservative non-instrumental treatment of benign prostatic hyperplasia |
| Q34053400 | Consultation patterns in a community survey of men with benign prostatic hyperplasia |
| Q74553189 | Controversies in the management of lower urinary tract symptoms: an overview |
| Q39443380 | Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound |
| Q53365997 | Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score |
| Q73807678 | Correlation of presumed circle area ratio with infravesical obstruction in men with lower urinary tract symptoms |
| Q38058185 | Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system |
| Q88636939 | Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia |
| Q33898821 | Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction |
| Q45339114 | Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model |
| Q73944699 | Detailed interstitial temperature mapping during treatment with a novel transurethral microwave thermoablation system in patients with benign prostatic hyperplasia |
| Q71525361 | Detailed prostatic interstitial thermal mapping during transurethral grooved rollerball electrovaporization and loop electrosurgery for benign prostatic hyperplasia |
| Q48055469 | Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia |
| Q44760919 | Development of a quality of life scale specific for patients with benign prostatic hyperplasia |
| Q35603076 | Diagnosis and treatment of voiding symptoms |
| Q40660567 | Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth? |
| Q43698829 | Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia |
| Q34553699 | Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia? |
| Q42632921 | Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis. |
| Q33983912 | Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects |
| Q71703269 | Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men |
| Q53163119 | Drug Concentration in Rat Plasma, Bladder, and Prostate After Mirodenafil Administration in a Chronic Pelvic Ischemia Model |
| Q35203797 | Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life |
| Q35964540 | Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. |
| Q72077750 | Economic Burden of Treated Benign Prostatic Hyperplasia in the United Kingdom |
| Q44610306 | Effect of Age on Hydrogen Peroxide Mediated Contraction Damage in the Male Rat Bladder |
| Q48690751 | Effect of Depression on the Risk and Severity of Lower Urinary Tract Symptoms in Community-Dwelling Elderly Korean Men. |
| Q53417776 | Effect of administration mode (patient vs physician) and patient's educational level on the Turkish version of the International Prostate Symptom Score. |
| Q37085210 | Effect of tamsulosin on ejaculatory function in BPH/LUTS |
| Q24632591 | Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials |
| Q33262634 | Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia |
| Q53570192 | Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study |
| Q40089634 | Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up |
| Q73503624 | Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology |
| Q53274302 | Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners |
| Q34428486 | Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score |
| Q41561784 | Epidemiology and Natural History of Benign Prostatic Hyperplasia |
| Q33633711 | Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea |
| Q42515814 | Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia |
| Q24793732 | Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate |
| Q50948995 | Factors affecting health-related quality of life among patients with lower urinary tract symptoms |
| Q71812233 | Finasteride and benign prostatic hyperplasia |
| Q51305552 | Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms |
| Q30332529 | Frequency of sexual activity and prostatic health: fact or fairy tale? |
| Q42251019 | HMGB1: A potential target for treatment of benign prostatic hyperplasia |
| Q39088482 | Health care sought and received by men with urinary symptoms, and their views on prostatectomy. |
| Q74326909 | Health status and its correlates among Dutch community-dwelling older men with and without lower urogenital tract dysfunction |
| Q39088473 | Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. |
| Q53581804 | Health-related quality of life associated with lower urinary tract symptoms in four countries |
| Q33547191 | High intensity focused ultrasound in benign prostatic hyperplasia |
| Q40768004 | High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation |
| Q44282716 | Hydrogen-potassium ATPase inhibitors induce relaxation on rabbit prostatic strips in vitro |
| Q37209797 | Hyperglycemia, Hyperinsulinemia, Insulin Resistance, and the Risk of BPH/LUTS Severity and Progression Over Time in Community Dwelling Black Men: The Flint Men's Health Study |
| Q51146826 | Impact of benign prostatic hyperplasia on general well‐being of men |
| Q73935733 | Impact of medical therapy on transurethral resection of the prostate: a decade of change |
| Q34372028 | Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. |
| Q35085419 | In a free healthcare system, why do men not consult for lower urinary tract symptoms (LUTS)? |
| Q44464964 | Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States |
| Q33845859 | Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project |
| Q39438002 | Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. |
| Q36911891 | Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis |
| Q53278224 | International Prostate Symptom Score--IPSS-AUA as discriminat scale in 400 male patients with lower urinary tract symptoms (LUTS). |
| Q34192671 | Introducing holmium laser enucleation of the prostate alongside transurethral resection of the prostate improves outcomes of each procedure |
| Q61613819 | Introduction |
| Q80296330 | Is nighttime voiding normal or anomalous? |
| Q47363329 | Is there a correlation |
| Q35629578 | Large diverticulum of the urinary bladder: A rare cause of deep vein thrombosis with consecutive pulmonary embolism |
| Q42607707 | Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension |
| Q61613724 | Lower urinary tract symptoms in men |
| Q53299066 | Lower urinary tract symptoms of men seeking medical care--comparison of symptoms found in the clinical setting and in a community study |
| Q39555900 | Male patients with lower urinary tract symptoms. 1: Assessment |
| Q36116524 | Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile |
| Q34767574 | Medical therapy for benign prostatic hyperplasia progression |
| Q40902682 | Medical therapy for benign prostatic hyperplasia: the road ahead |
| Q44281791 | Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. |
| Q74544871 | Meta-Analysis of Randomized Clinical Trials of Finasteride |
| Q38983706 | Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases? |
| Q44522571 | Mirabegron for Male Lower Urinary Tract Symptoms |
| Q33579874 | Mortality is associated with inflammation, anemia, specific diseases and treatments, and molecular markers |
| Q35001406 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensi |
| Q44031270 | N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists |
| Q53249054 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study |
| Q52902541 | Natural History and Epidemiology of Benign Prostatic Hyperplasia: Relationship Among Urologic Measures |
| Q53373551 | Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community |
| Q45298071 | Natural history of lower urinary tract symptoms in Japanese men from a 15‐year longitudinal community‐based study |
| Q73366412 | Natural history of lower urinary tract symptoms in men—result of a longitudinal community-based study in Japan |
| Q24648955 | New words for old: lower urinary tract symptoms for "prostatism" |
| Q42141212 | Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia |
| Q42128261 | Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype |
| Q43333330 | Older men?s concerns about their urological health: a qualitative study |
| Q58555990 | Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study |
| Q26744685 | Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South Korea |
| Q77164546 | Pathophysiological relationships between lower urinary tract symptoms and the prostate do not strengthen over time |
| Q44779375 | Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. |
| Q38067838 | Patient Selection and Counseling before Prostatic Arterial Embolization |
| Q40901915 | Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational s |
| Q35782419 | Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? |
| Q38198534 | Pelvic ultrasound evaluation for benign prostatic hyperplasia: prediction of obstruction |
| Q42547818 | Perceptions of urinary symptoms and health-care-seeking behaviour amongst men aged 40-79 years |
| Q39261903 | Persistent detrusor overactivity in rats after relief of partial urethral obstruction |
| Q44237117 | Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment |
| Q35871178 | Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician |
| Q57595115 | Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms |
| Q93336545 | Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia |
| Q24199135 | Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia |
| Q33671875 | Phytoestrogens and diseases of the prostate gland |
| Q28204203 | Phytomedicines for the prostate |
| Q34037407 | Polypharmacy in the HIV-infected older adult population |
| Q74640719 | Possible Relationship between Dietary Factors and Pathogenesis of Prostate Cancer |
| Q42337531 | Post-cholecystectomy symptoms after laparoscopic cholecystectomy. |
| Q35894959 | Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the Prostate |
| Q39771272 | Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: Results of a regional population-based survey and comparison with industrialized nations |
| Q33863130 | Prevalence and management status of urologic disease in geriatric hospitals in South Korea: A population-based analysis |
| Q36758112 | Prevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Community-based Survey |
| Q39832304 | Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older |
| Q53553254 | Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. |
| Q39463638 | Prevalence of lower urinary tract symptoms in Finnish men: a population‐based study |
| Q43605317 | Prevalence of lower urinary tract symptoms in a community-based survey of men in Turkey |
| Q36598330 | Preventing progression in men with mild symptoms of benign prostatic hyperplasia: a potential role for phytotherapy. |
| Q37085376 | Profile of men's health in Malaysia: problems and challenges |
| Q104288383 | Prostate Artery Embolization: State of the Evidence and Societal Guidelines |
| Q93795274 | Prostate Cancer: Progression, Risk Reduction, and Future Options |
| Q91873183 | Prostate artery embolisation: an initial experience from an Indian perspective |
| Q58171068 | Prostate cancer and tumor stage-dependent circadian neuroendocrine disturbances |
| Q41450459 | Prostate disease: epidemiology, natural history and demographic shifts |
| Q36680166 | Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group |
| Q89570965 | Prostate embolization: patient selection, clinical management and results |
| Q39424650 | Prostate screening--the Singapore experience |
| Q33911754 | Prostate volume measurement by transrectal ultrasonography: comparison of height obtained by use of transaxial and midsagittal scanning. |
| Q48064861 | Prostatic artery embolization in benign prostatic hyperplasia: preliminary results in 13 patients |
| Q39023194 | Prostatic artery embolization in treating benign prostatic hyperplasia: a systematic review |
| Q30658039 | Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis |
| Q51959950 | Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study |
| Q52062612 | Questioning questions about symptoms of benign prostatic hyperplasia |
| Q80298312 | Reducing the risk of benign prostatic hyperplasia progression |
| Q44390740 | Regulation of angiotensin II receptors in the prostate of the transgenic (mRen-2)27 rat: effect of angiotensin-converting enzyme inhibition |
| Q37727466 | Relationship Between Alcohol Consumption and Prostatic Hyperplasia According to Facial Flushing After Drinking in Korean Men. |
| Q36758168 | Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men |
| Q39377627 | Relationship between Prostate Specific Antigen, Prostate Volume and Age in the Benign Prostate |
| Q71306005 | Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH) |
| Q37074170 | Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men |
| Q39820611 | Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. |
| Q72086795 | Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia |
| Q40024507 | Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia |
| Q80340179 | Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia |
| Q35162908 | Review of current and future approaches to the management of benign prostatic hyperplasia |
| Q61569027 | Risk factors for lower urinary tract symptoms in southern Chinese men |
| Q35808841 | Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study |
| Q48955189 | Role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and single-institutional analysis |
| Q43425950 | Role of the renin-angiotensin system in the nandrolone-decanoate-induced attenuation of the Bezold-Jarisch reflex |
| Q36284747 | Roles of Urology as Assessed by an Analysis of Inpatients Referred to Urology |
| Q40300137 | Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008. |
| Q72080378 | Serum Concentration of Prostate-Specific Antigen in Relation to Prostate Volume in 50 Healthy Middle-Aged Men |
| Q46967086 | Serum lipid levels in benign prostatic hyperplasia |
| Q50919961 | Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians. |
| Q71700470 | Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate |
| Q37127902 | Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? |
| Q58256295 | Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years |
| Q48046988 | Silodosin causes impaired ejaculation and enlargement of seminal vesicles in sexually active men treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia |
| Q40274998 | Simple case definition of clinical benign prostatic hyperplasia, based on International Prostate Symptom Score, predicts general practitioner consultation rates |
| Q34380392 | Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms |
| Q36195120 | Statistical Approach for Assessing the Influence of Calcium Silicate and HPMC on the Formulation of Novel Alfuzosin Hydrochloride Mucoadhesive-Floating Beads as Gastroretentive Drug Delivery Systems |
| Q53337361 | Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status |
| Q46481688 | Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). |
| Q41318850 | Symptom scores in benign prostatic hyperplasia |
| Q51371258 | Synergistic Effect by Co-Administration of Tamsulosin and Solifenacin on Bladder Activity in Rats. |
| Q34463058 | Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects |
| Q34597840 | Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms |
| Q34492626 | Tamsulosin: an update of its role in the management of lower urinary tract symptoms |
| Q41604940 | Technique considerations and complication management in transurethral resection of the prostate and photoselective vaporization of the prostate. |
| Q30248685 | The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates |
| Q35799969 | The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function |
| Q49112131 | The Investigation of Relationship between Coronary Artery Ectasia, Benign Prostatic Enlargement, and Lower Urinary Tract Symptoms |
| Q48457948 | The Potential Role of a Self-management Intervention for Benign Prostate Hyperplasia |
| Q72097026 | The Prostatron Transurethral Microwave Device in the Treatment of Bladder Outflow Obstruction due to Benign Prostatic Hyperplasia |
| Q46840797 | The Relationship Between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and the Number of Components of Metabolic Syndrome |
| Q35834345 | The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy |
| Q34707742 | The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia |
| Q42632937 | The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia |
| Q39297278 | The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia |
| Q85113137 | The effect of in vitro ischemia/reperfusion on contraction, free fatty acid content, phospholipid content, and malondialdehyde levels of the rabbit urinary bladder |
| Q55216147 | The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia. |
| Q38628166 | The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. |
| Q39088490 | The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy |
| Q36054510 | The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis |
| Q35821086 | The link between LUTS and ED: clinical and basic science evidence |
| Q34080438 | The natural history of benign prostatic hyperplasia: what have we learned in the last decade? |
| Q41592691 | The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination |
| Q28082321 | The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys |
| Q40790544 | The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. |
| Q34267495 | The prevalence of lower urinary tract symptoms in korean men aged 40 years or older: a population-based survey |
| Q81154710 | The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH |
| Q38104737 | The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). |
| Q35993920 | The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia |
| Q35212506 | The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia |
| Q31088060 | The use of lasers in benign prostatic enlargement |
| Q89273274 | Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis |
| Q40469905 | Total healthcare budget: Assigning priority and level of asset allocation to the diagnosis and management of urologic diseases |
| Q40488399 | Transdermal Dihydrotestosterone Treatment of 'Andropause' |
| Q74396445 | Transrectal Ultrasonic Planimetry of the Prostate in Relation to Age and Lower Urinary Tract Symptoms among Elderly Men in Japan |
| Q73930513 | Transurethral hot-water balloon thermoablation for benign prostatic hyperplasia: patient tolerance and pathologic findings |
| Q39443245 | Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? |
| Q33390522 | Transurethral resection of the prostate in Northern Nigeria, problems and prospects |
| Q61807830 | Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis |
| Q74553220 | Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients |
| Q39458047 | Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective |
| Q33821256 | Treatment of nocturia in the elderly |
| Q85205488 | Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article |
| Q72081756 | Ultrasonically Determined Patterns of Enlargement in Benign Prostatic Hyperplasia |
| Q33953804 | Ultrasonography and abdominal radiography versus intravenous urography in investigation of urinary tract infection in men: prospective incident cohort study |
| Q41200146 | Underdetection of clinical benign prostatic hyperplasia in a general medical practice |
| Q36360868 | Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate |
| Q50069063 | Urethral Reconstruction in Aging Male Patients |
| Q33702701 | Urinary symptoms: prevalence and severity in British men aged 55 and over |
| Q36870262 | Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction |
| Q39458238 | Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. |
| Q43060743 | Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. |
| Q40902136 | Urologic manpower issues for the 21st century: assessing the impact of changing population demographics |
| Q34707405 | Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients |
| Q44665635 | Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study |
| Q81160842 | Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms |
| Q33605045 | Vitamin D deficiency and lower urinary tract symptoms in males above 50 years of age. |
| Q53325241 | Voided volumes: normal values and relation to lower urinary tract symptoms in elderly men, a community-based study. |
| Q83781556 | Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males |
| Q40403580 | Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia |
| Q79291646 | [Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia] |
Search more.